Cervical cancer trial left tumour heating unmeasured
For women with cervical cancer, it is unclear whether this device heats tumours enough to make radiation more effective.
The question the lab is investigating
Can the low-power 'modulated electro-hyperthermia' device that a South African randomised trial added to chemoradiotherapy for cervical cancer (planned at 90 to 130 watts) actually raise the temperature of a deep pelvic tumour enough to sensitise it to radiation, judged by patient-specific electromagnetic and heat simulations across many real pelvic anatomies?
What's going on
- A trial reported better local cancer control after adding a low-power heating device.
- Nobody measured tumour temperatures to check whether enough heat reached the cancer.
Why it's stuck
- The record found no simulation of this device's pelvic heating using real patient anatomies.
- Heating researchers mostly study higher-power devices; proponents say heat is not the main effect.
What we'd try
- The lab would first try to reproduce published heating simulations and temperature measurements.
- It would simulate tumour heating across real pelvic anatomies at the trial's power settings.
- It would test uncertainty and compare results with a conventional high-power heating system.
Where we stand
- Open after initial review; the lab rates how checkable the question is at 2 out of 5.
- Earlier physics work may already settle the question.
- Patient temperature data for checking results come from one small manufacturer-reported study.
Written by the lab's AI (openai/gpt-6.1-sol) and checked against the lab's record by a model from another company (google/gemini-4-argon). The record has changed since. A new summary is on its way.
- Good it would do
- 2 / 5
- Can AI help
- 3 / 5
- How neglected
- 4 / 5
- Can we check it
- 3 / 5
Read the lab's full wording
Why it's on hold
Park. A many-anatomy simulation of the low-power device is feasible with public CTs and open solvers, but the field's experts (a 2026 review co-written by the trial lead) already doubt that 90-130 W reaches therapeutic tumour temperatures, the real dispute is about non-thermal effects, and no decision-maker was found who would use the result; the fence checker's fatal objection stands.
Why it's stuck
The device is promoted for low-resource settings, and the South African trial (Minnaar and colleagues, PLoS One 2019, 210 women randomised, many HIV-positive) reported higher six-month local disease control with it (45.5% against 24.1%, p = 0.003). The trial's authors say the device costs less than half the price of a brachytherapy device and is 'suitable for investigating as a chemo-radiosensitiser in a low-resource setting'.
What we'd try
Build anatomical models of the female pelvis from public segmented scans (for example the TotalSegmentator MRI dataset on Zenodo, 1,296 scans with 50 segmented structures, CC-BY 4.0, and its CT counterpart), place a cervical tumour of realistic size, model the device's capacitive electrodes and water bolus at 13.56 MHz, and solve the electro-quasistatic field and the Pennes bioheat equation for each anatomy at 90, 110 and 130 W. Report the distribution across patients of the tumour temperature reached, and the thermal dose (CEM43), with tissue-property and perfusion uncertainty propagated by Monte Carlo sampling.
We'd look again if
An expert from the ESHO capacitive hyperthermia working group (e.g. Kok or Crezee, Amsterdam UMC; the Charite group) or the trial team says a many-anatomy simulation would narrow a live uncertainty, or commits to using it to design thermometry or power settings in the planned South African rollout or a replication trial; and the 30 cm electrode and coupling details become available.
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0217894
Think we got it wrong?
Ruled-out problems can come back. Tell us what we missed.
Members can read the full record for this problem, check its sources and comment. Open the member view → Not a member? Here is how to join.